What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2023-02-28 compared with 2022-02-28 · 28 added, 3 removed, 5 unchanged (86% of the section changed)

1 unchanged sentence

From time to time, we may be subject to other various legal proceedings and claims that arise in the ordinary course of our business activities.

Although the results of litigation and claims cannot

be predicted with certainty, we do not believe we are party to any other claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on

our business.

Although the results of litigation and claims cannot be predicted

with certainty, we do not believe we are party to any other claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our

Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

1 unchanged sentence

Not Applicable.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market

Our common stock is traded on the NASDAQ Global Market under the symbol “RCKT” and on the NASDAQ Biotechnology Index (NASDAQ:

On February 22, 2023, the last reported sale price for our

common stock on the Nasdaq Global Market was $19.20 per share.

Stock Performance Graph

The graph set forth below compares the cumulative total stockholder return on our common stock between January 1, 2017 and December 31, 2022 with the cumulative total return of (a) the NASDAQ Biotechnology Index

and (b) the NASDAQ Composite Index, over the same period.

This graph assumes the investment of $100 on January 1, 2017 of our common stock, the NASDAQ Biotechnology Index and the NASDAQ Composite Index and assumes the reinvestment of dividends,

The comparisons shown in the graph below are based upon historical data.

We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the

potential future performance of our common stock.

As of February 22, 2023, there were 45 stockholders of record, which excludes stockholders whose shares were held in nominee or street name by brokers.

We previously

completed a reverse merger with Inotek Pharmaceuticals Corporation (“Inotek”) which closed on January 4, 2018.

The stock performance information prior to January 4, 2018, represents the share price of our predecessor company Inotek prior to the

reverse merger as adjusted for a 4 for 1 reverse split completed upon the reverse merger.

Dividend Policy

We have never declared or paid any cash dividends on our capital stock.

We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business

and we do not anticipate paying any cash dividends in the foreseeable future.

Any future determination to pay cash dividends will be made at the discretion of our Board of Directors..

Investors should not purchase our common stock with the

expectation of receiving cash dividends.

Recent Sales of Unregistered Securities

Issuer Purchases of Equity Securities

There were no repurchases of our common stock during the year ended December 31, 2022.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings